atepeq/tico19 huggingface dataset:
Hussein A A, et al studied several candidate compounds which then optimized and analyzed for their skeleton similarity with the highest similar approved drugs in order to accelerate a potent anti-SARS-CoV-2 drug development in his preclinical study to be recommended in a clinical study design.
Hussein AA, et al. jaangi hawtirdeji lekki foondol je o hoosi e larti naandol suudu ha ɓawo man, e sappini naandolji jur be lekki je jarfotto ngam yaawinugo ko footi wona lekki kanduɗum je mbardatta SARS-CoV-2 ha nder ekkitol mako je hiddeko ngam feelugo ha nder dabare ekkitol ha suudu lekki.
Chloroquine is an anti-malarial medication that is also used against some auto-immune diseases.
Chloroquine woni lekki paaɓooje je ɗon feeli ngam nyauji feere bo'o.
On 18 March, the WHO announced that chloroquine and the related hydroxychloroquine would be among the four drugs studied as part of the Solidarity clinical trial.
Ha 18 Maars, WHO matini yo'o chloroquine be hydroxychloroquine footi wona ha cakka lekki je don nder ekkitol foondol ha suudu lekki Solidarity.
New York governor Andrew Cuomo announced that New York State trials of chloroquine and hydroxychloroquine would begin on 24 March.On 28 March, the FDA authorized the use of hydroxychloroquine sulfate and chloroquine phosphate under an Emergency Use Authorization (EUA).
Ngomna New York Andrew Cuomo matini yo'o foondolji New York State do chloroquine be hydroxychloroquine footi fuɗɗa ha 24 Maars. Ha 28 Maars, FDA jarfi hoccol hydroxychloroquine sulfate be chloroquine phosphate to wodi jaawal Emergency Use Authorization (EUA).
The treatment has not been approved by the FDA's clinical trials process and is authorized under the EUA only as an experimental treatment for emergency use in patients who are hospitalized but are not able to receive treatment in a clinical trial.
Laahal foondolji ha suudu lekki FDA jarfay hurgol ngol tawon e ɗon jarfi sna be hasduye EUA bana hurgol foondol tan to wodi jaawal be hurgol ha nyauɓe je wondi ha suudu lekki amma je footay keɓɓa hurgol ha lartol suudu lekki.
The CDC has said that "the use, dosing, or duration of hydroxychloroquine for prophylaxis or treatment of SARS-CoV-2 infection" are not yet established.
CDC wi'i yo'o "hoosugo, hokkugo, mala neeɓugo hydroxychloroquine ngam prophylaxis mmala hurgol nyau SARS-CoV-2" jarfakke tawon.
Doctors have said they are using the drug when "there's no other option".
Lekkitoɓe wi'i yo'o ɓe ɗon hokka lekki man to "wala dabare feere".
A Turkish research team in Istanbul is conducting a small study on the use of chloroquine in combination with zinc, vitamin A, vitamin C and vitamin D.
Geeɓe teffol Turkia'en feere ha Istanbul ɗon sallina ekkitol feere do chloroquine be zinc, vitamin A, vitamin C be vitamin D.
Large studies are underway at Duke University and the University of Oxford.
Ekkitolji feere maungel ɗon do lawol ha Duke University be University of Oxford.
NYU Langone Medical School is conducting a trial on the safety and efficacy of preventative use of hydroxychloroquine.
NYU Langone Medical School ɗon waɗa foondol do jam e naffuda hoosugo hydroxychloroquine bana dabare aynol.
Chinese clinical trials in Wuhan and Shenzhen claimed to show favipiravir was "clearly effective".
Foondolji ha suudu lekki Cayna ha Wuhan be Shenzhen wi'i yo'o favipiravir ɗon "naffa masin".
35 patients in Shenzhen tested negative in a median of 4 days, while the length of illness was 11 days in the 45 patients who did not receive it.
Nyauɓe 35 ha Shenzhen larti bana maray nyau ha nder balɗe 4, e juttol nyau man bo'o balɗe 11 ha cakka nyauɓe 45 je hoosay ɗum.
In a study conducted in Wuhan on 240 patients with pneumonia, half were given favipiravir and half received umifenovir.
Ha nder ekkitol feereha Wuhan ha do nyauɓe 240 be pneumonia, reeta maɓɓe hoosi favipiravir be reeta maɓɓe hoosi umifenovir.
The Italian Pharmaceutical Agency reminded the public that the existing evidence in support of the drug is scant and preliminary.
Italian Pharmaceutical Agency matini ummatore yo'o sappinolji do wallende lekki ndu moftay tawon e jarfay.
On 2 April, Germany announced that it would purchase the drug from Japan for its stockpile, and use the military to deliver the drug to university hospitals, where the drug will be used to treat COVID-19 patients.
Ha 2 Aviiril, Jaamani matini yo'o o soddan lekki ha Japan ngam ɗon mofti ha ton, soje'en ngam addugo lekki man ha suuɗi lekki jam'iareji, e lekki man wonan ngam hurgugo nyauɓe COVID-19.
According to the South China Morning Post, Shinzo Abe has made overtures to the Trump administration about purchasing the drug.The drug may be less effective in severe cases of illness where the virus has already multiplied.
Ha South China Morning Post, Shinzo Abe arti ngomna Trump ngam soddugo lekki. Lekki footi wona maray sembe jur ha hurgol nyauɓe je nyau maɓɓe ɗon nyaɗi, e viriis man nufti timmi.
It may not be safe for use by pregnant women or those trying to conceive.
Footi wonatta boɗɗu ha rewɓe be reedu hoosa ndu mala ɓe'en je yiɗi hoosugo reedu.
One study of lopinavir/ritonavir (Kaletra), a combination of the antivirals lopinavir and ritonavir, concluded that "no benefit was observed".
Ekkitol feere do lopinavir/ritonavir (Kaletra), hawtirde lopinavir be ritonavir je ɗon mbarda viriis, wi'i yo'o "wala naffuda je tawama".
The drugs were designed to inhibit HIV from replicating by binding to the protease.
Lekki ndi wurti ngam tuttugo HIV gal nuftugo gal hawtugo be protease.
A team of researchers at the University of Colorado are trying to modify the drugs to find a compound that will bind with the protease of SARS-CoV-2.There are criticisms within the scientific community about directing resources to repurposing drugs specifically developed for HIV/AIDS.
Geeɓe teffooɓe ha University of Colorado yiɗi saanjugo lekki ngam heɓɓugo hawtirde je footi hawta be protease SARS-CoV. Wodi lasbinolji ha kunde ummatore teffooɓe ngam ɗowugo kujeji ngam laritugo lekki je wurtini ngam HIV/AIDS.
The WHO included lopinavir/ritonavir in the international Solidarity trial.
WHO watti lopinavir/ritonavir ha nder foondol lesdi feere-feere Solidarity .
Remdesivir was created and developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections . Gilead Sciences subsequently discovered that Remdesivir had antiviral activity in vitro against multiple filo-, pneumo-, paramyxo-, and corona- viruses .
Remdesivir waɗɗotto e wurtinama gal Gilead Sciences bana hurgol nyau viriis Ebola be nyauji viriis Marburg. Gilead Sciences tawi fahin bo'o Remdesivir ɗon mari kuɗe je ɗon mbarda viriis in vitro do viriisji jur bana filo-, pneumo-, paramyxo-, be korona.
One issue with antiviral treatment is the development of resistance through mutations that can lead to more severe disease and transmission.
Larula gooto ngam hurgol viriis woni neeɓugo gal saanjolji, ko footi yara ha nyau je ɓuri nyaɗugo be sallinol.
Some early pretrial studies suggest remdesivir may have a high genetic barrier to resistance.There are several clinical trials underway, including two conducted by Cleveland University Hospitals; one for people with moderate illness and another for those with more severe illness.
Ekkitolji feere je fuɗɗi hiddeko foondol ɗon wi'a yo'o remdesivir footi mara keleewol gene ngam neeɓugo. Wodi foondolji ha suudu lekki je ɗon salla jonta, bana ɗiɗi je ɗon fadi gal Cleveland University Hospitals; gooto ngam yimɓe be nyau deydey be feere ngam ɓe'en je ɗon mari nyau je ɓuri nyaɗugo.
There are three ongoing clinical trials of intravenous vitamin C for people who are hospitalized and severely ill with COVID-19; two placebo controlled (China, Canada) and one with no control (Italy).
Wodi foondolji ha suudu lekki tati je vitamin C je sallan nder lawol iyam ha yimɓe je ɗon wondi ha suudu lekki e ɗon mari COVID-19 je nyaɗungel; placebo je ɗon ayni ɗiɗi (Cayna, Kanada) be gooto je wala aynugo (Italy).
New York State began trials for the antibiotic azithromycin on 24 March 2020.
New York State fuɗɗi foondolji ngam antibiotik azithromycin ha 24 Maars 2020.
Japan's National Center for Global Health and Medicine (NCGM) is planning a clinical trial for Teijin's Alvesco (ciclesonide), an inhaled corticosteroid for asthma, for the treatment of pre-symptomatic patients infected with the novel coronavirus.
Japan's National Center for Global Health and Medicine (NCGM) ɗon waɗa jaahargal do foondolji ha suudu lekki ngam Teijin's Alvesco (ciclesonide), corticosteroid je mustugo ngam nyau dule, ngam hurgol nyauɓe je maray mandolji nyau tawon je raɓɓi koronaviriis keese.
A form of angiotensin-converting enzyme 2, a Phase II trial is underway with 200 patients to be recruited from severe, hospitalized cases in Denmark, Germany, and Austria to determine the effectiveness of the treatment.
Irin angiotensin-converting enzyme 2, foondol Yaɓɓorde II ɗon do sallugo be nyauɓe 200 je ɓe suɓɓan no ha cakka ɓe'en je nyau man nyaɗi masin, wondi ha suudu lekki ha Denmark, Jaamani, be Ostriya ngam fammugo naffuda hurgol.
Researchers from the Montreal Heart Institute in Canada are currently studying the role of colchicine in reducing inflammation and pulmonary complications in patients suffering from mild symptoms of COVID-19.
Teffooɓe ha Montreal Heart Institute ha Kanada ɗon jaanga kugal colchicine ngam ustugo huudure be nyaji fuffu ha nyauɓe je ɗon mari mandolji COVID-19 deydey.
The study, named COLCORONA, is recruiting 6000 adults aged 40 and over who were diagnosed with COVID-19 and experience mild symptoms not requiring hospitalization.
Ekkitol, ewnotto COLCORONA, ɗon hoosa mauɓe 6000 je mari duɓɓi mala ɓuri je tawotto mari nyau COVID-19 e mari mandolji je maray haaje yahugo ha suudu lekki.
Women who are pregnant or breastfeeding or who do not have an effective contraceptive method are not eligible.
Rewɓe je ɗon be reedu mala je ɗon musina mala mo je maray dabare siwtugo footay hoosa.
Several anticoagulants are being tested in Italy.
Anticoagulantji jur ɗon do lartol ha Italy.
Low-molecular-weight heparin is being widely used to treat patients, prompting the Italian Medicines Agency to publish guidelines on its use.
Heparin je ɗon mari molecule je ɗon lessi ɗon waagare nder hurgol nyauɓe, ko waɗi Italian Medecine Agency wurtina dabareji ngam huwugo be man.
A multicenter study on 300 patients researching the use of enoxaparin sodium at prophylaxis and therapeutic dosages was announced in Italy on April 14.
Wakkere ekkitol feere do nyauɓe 300 je ɗon do teffugo kugal enoxaparin sodium ha prophylaxis be dabare hoosugo matinama ha italy ha 14 Aviiril.
Since SARS-CoV-2 is a virus, considerable scientific attention has been focused on repurposing approved anti-viral drugs that were developed for prior outbreaks such as MERS, SARS, and West Nile virus.
Nde SARS-CoV-2 lati viriis, hakkika aandal wondi ngam laritugo lekki je mbardatta viriis je wangi hiddeko nyauji bana MERS, SARS, be viriis West Nile.
Ribavirin: ribavirin was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Ribavirin: ribavirin feelama ngam hurgol COVID-19 bana limtol batakkewol sappinol 7 Cayna
Umifenovir: umifenovir was recommended for COVID-19 treatment according to Chinese 7th edition guidelines
Umifenovir: umifenovir feelama ngam hurgol COVID-19 bana limtol batakkewol sappinol 7 Cayna
Some antibiotics that have been identified as potentially repurposable as COVID-19 treatments:
Antibiotikji feere je ɗon maandi bana footi larita ndu bana dabare hurgol COVID-19:
Tocilizumab (Anti-IL-6 receptor): Approved by China.
Tocilizumab (Anti-IL-6 receptor): Cayna jaɓɓi.
Also trials in Italy and China. and see Tocilizumab#COVID-19.
Fahin bo'o foondolji ha Italy be Cayna. e lare Tocilizumab#COVID-19.
It is unclear yet whether conditions arising during pregnancy including diabetes, cardiac failure, hypercoagulability or hypertension might represent additional risk factors for pregnant people as they do for nonpregnant people.From the limited data available, vertical transmission during the third trimester probably does not occur, or only occurs very rarely.
Laɓɓay ha jonta to larulaji je ummikki ha wakati reedu larni nyau sukar, nyau ɓernde, iyam je ɗon ɗacca law mala illam iyam be sembe footi wona sababu je ɗon ɓesda nyau ha rewɓe je ɗon be reedu. Ngam matinolji je wonay jur, sallinol gal do ha ta'irde tataɓool footi wondatta, mala ɗon yotta ndego-ndego.
There is no data yet on early pregnancy.
Wala matinolji ha jonta do reedu je yotti law.
Little evidence exists to permit any solid conclusions about the nature of COVID-19 infection in pregnancy.
Sappinolji pamarron wondi ngam jabbuyeji do nyau COVID-19 ha rewɓe be reedu.
A case series of 43 women from New York who tested positive for COVID-19 showed similar patterns to non-pregnant adults: 86% had mild disease, 9.3% had severe disease and 4.7% developed critical disease.
Wodi rewɓe 43 ha New York je larti bana mari nyau COVID-19 sappini irin mandolji be mauɓe je wonday be reedu: 86% ɗon mari nyau je ɗon deydey, 9.3 ɗon no mari nyau je nyaɗum be 4.7 je mari nyau je ɓuri nyaɗugo.
Fetal distress was reported in two.
Ha kunde maɓɓ ɗiɗi mari no larula be ɓingel.
None of the women developed severe COVID-19 pneumonia or died.
Wala goɗɗo ha cakka rewɓe ndu mari pneumonia COVID-19 je ɗon nyaɗi mala mayi.
All of them had live birth pregnancies and no severe neonatal asphyxia was observed.
Fu maɓɓe mari no reedu ɓesni fu e wala mo je hollini asphyxia ɓingel keese.
The samples of breast milk, amniotic fluid, cord blood and neonatal throat swab were tested for SARS-CoV-2, and all results were negative.In another study on 15 pregnant women, majority of the patients presented with fever and cough, while laboratory tests yielded lymphocytopenia in 12 patients.
Leekuji kossam, ndiyam reedu, iyam jabburu, be leeku tuɗe ɓingel danyinki lartotto ngam SARS-CoV-2, e sappinolji fu holli wala nyau. Ha nder ekkitol feere rewɓe be reedu 15, ɓurna nyauɓe ɗon no sappina wullol ɓaandu be sondaru, gal wakkere feere bo'o lartolji suudu lartol mari no lymphocytopenia 12.
Computed tomography findings of these patients were consistent with previous reports of non-pregnant patients, consisting of ground-glass opacities at early stage.
Sappinolji ta'irdeji be ordo nyauɓe ndu yahidi be sappinolji nyauɓe je wala reedu je sallingo, be yiɓre bana darugal ha fuɗɗorde man.
Follow-up images after delivery showed no progression of pneumonia.Media reports indicate that over 100 women with COVID-19 might have delivered, and in March 2020, no maternal deaths were reported.
Fotoji laynol ha ɓawo ɓesnugo hollay yahde pneumonia. Batakkeji hubaru matini yo'o ɓuri rewɓe 100 be COVID-19 footi ɓesni, e ha Maars 2020, wala mayde daada je matinama.
Their guidelines thus advise that any pregnant person admitted to hospital with a COVID-19 infection should receive at least 10 days of prophylactic low-molecular-weight heparin after being discharged from the hospital.
Laahalji maɓɓe ɗon feela kadi kala debbo je ɗon mari reedu je nasti ha suudu lekki be nyau COVID-19 sey hokke balɗe 10 ngam heparin je mari molecul prophylactic je lessi ha ɓawo wurtol ha suudu lekki.
There are no data yet concerning the implications of COVID-19 infections for labour.
Wala matinolji je ɗon larni nyau COVID-19 ngam ɓesnugo.
One infant girl born to a mother with COVID-19 had elevated IgM levels two hours after birth, suggesting that she had been infected in utero and supporting the possibility of vertical transmission in some cases.
Woɗi debbo feere je mari COVID-19 ɓesni ɓingel debbo be IgM ɗon wa'i ha ɓawo dayinki, ko ɗon holla yo'o o raɓɓi nyau ndu ha reedu e ɗon sappina bo'o sallinol diga do ha les ha yakke feere.
A small study involving 6 confirmed COVID-19 mothers showed no indication of SARS-COV-19 in their newborns' throats or serum but antibodies were present in neonatal blood sera samples, including IgM in two of the infants.
Ekkitol feere be daadaji 6 je ɗon aandi nyau COVID-19 sappinay mandolji SARS-CoV-19 ha daande mala neebam ɓaandu ɓikkon maɓɓe amma fadooɓe ɓaandu ɗon no ha nder leeku iyam, bana IgM ha cakka ɓikkon ɗiɗi.
This is not usually passed from mother to fetus so further research is required to know whether the virus crossed the placenta or whether placentas of women in the study were damaged or abnormal.
Ndu sallatta tum diga daada ha ɓingel ha reedu sey teffolji tokkita ngam fammugo to viriis ta'itti suudu ɓingel mala suuɗi ɓikkon rewɓe ha nder jaangirde ndu woni no.
Since COVID-19 shows similarities to SARS-CoV and MERS-CoV, it is likely that their effect on pregnancy are similar.
Nde COVID-19 ɗon mari naandolji be SARS-CoV be MERS-CoV, footi sababuji maɓɓe do reedu naanda.
Four of seven had first trimester miscarriage, two of five had fetal growth restriction in the second trimester, and four of five had preterm birth.
Nay nder joowey e ɗiɗi ruffi ha aranool ta'irde, ɗiɗi ha nder joowey mari darnol nder maunugo ɓingel ha nder reedu nder ta'irde ɗiɗaɓool, be danyinki hiddeko wakati man.
None of the newborns were infected with SARS-CoV.
Wala mo je mari nyau SARS-CoV ha kunde ɓikkon je ɓe danyi.
A report of ten cases of MERS- CoV infection in pregnancy in Saudi Arabia showed that the clinical presentation is variable, from mild to severe infection.
Matinol do nyauɓe MERS-CoV ha rewɗɓe be reedu sappo ha Saudi Arabiya sappini yo'o mandolji nyau footi sanja, diga kooyɗum ha nyaɗum.
The outcome was favorable in a majority of the cases, but the infant death rate was 27%.A recent review suggested that COVID-19 appeared to be less lethal to mothers and infants than SARS and MERS but that there may be an increased risk of preterm birth after 28 weeks' gestation.
Sappinol wondi kanduɗum ha ɓurna nyauɓe fu, amma limtol mayde ɗikkon lati 27%. Lartol keese holli yo'o COVID-19 woni bana mari limtol mayde je lessi ha daadiraɓe be ɓikkon do SARS be MERS amma footi sababuji feere do dayinki ha ɓawo asaweji reedu 28.
The World Health Organization and Centers for Disease Control and Prevention of the United States advises pregnant women to do the same things as the general public to avoid infection, such as covering cough, avoid interacting with sick people, cleaning hands with soap and water or sanitizer.
Geeɓe Duniyaru do Jam Ɓaandu be Ɗowirɗeji do Aynol e Lartol Nyau lesɗe America ɗon feela rewɓe be reedu ngaɗa kuje bana ummatore feere ngamm ta be nanga nyau bana suddu hunduko to bana ɗon sonda, ta joɗɗide be nyauɓe, lallugo juɗe be sabulu be ndiyam mala kuje laɓɓinugo.
A survey conducted in Shanghai among pregnant women in different trimesters of pregnancy identified a strong demand for online access to health information and services.
Emmolji feere je sallini ha Shangai ha kunde rewɓe be reedu ha nder ta'irdeji feere-feere ɗon maandi bana ewnandu kanduɗum ngam nastirde do hawo ha matinolji do jam ɓaandu be kuɗe.
People expecting their first baby were more willing to have online consultation and guidance than who had previously given birth.The RCOG and RCM recommend that in-person appointments be deferred by 7 days after the start of symptoms of COVID-19 or 14 days if another person in the household has symptoms.
Yimɓe je ɗon ndeena jippol ɓingel maɓɓe yardi no emmugo feelore gal hawo than ɓe'en je ɓesni timmi. RCOG be RCM ɗon feela yo'o ngidol gite be gite sey wonda ha ɓawo balɗe 7 diga fuɗɗam mandolji nyau COVID-19 mala balɗe 14 to goɗɗo feere ha saare ɗon mari maandolji nyau.
Fever subsequently developed in three asymptomatic patients.
Wullo ɓaandu wangi ha nyauɓe tati je maray mandolji.
One patient who had tested negative subsequently became symptomatic postpartum and tested positive three days after the initial negative test.
Nyauɗo gooto je larti bana maay nyau lati ɗon sappina mandolji nyau postpartum e larti mari nyau balɗe tati ha ɓawo larto je sappini o maray no nyau.
The doctors conducting the screening recommended that in order to reduce infection and allocate PPE, due to high numbers of patients presenting as asymptomatic, universal screening of pregnant patients should be conducted.
Lekkitaɓe je ngaɗatta lartol feeli yo'o ngam ustugo nyau e hokka PPE, ngam limgal nyauɓe je sappinata mondolji nyau, sey waɗa lartol nyauɓe je ɗon be reedu fu.
They also suggest that people with suspected or confirmed COVID-19 should have continuous electronic fetal monitoring.
Fahin, ɓe feeli yo'o yimɓe je bana mari nyau mala mari COVI-19 sey larta wonde ɓinge ha reedu tum be ordoji.
The use of birthing pools is not recommended for suspected or confirmed cases of COVID-19 due to the risk of infection via faeces.
Huwugo be tassawu dayugo nder ndiyam feelakke ha yimɓe je bana mari nyau mala je ɗon aandi mari COVID-19 ngam sababu sallinugo gal buuwe.
In the UK, official recommendations state that precautionary separation of a mother and a healthy baby should not be undertaken lightly and that they should be kept together in the postpartum period where neonatal care is not required.Literature from China recommended separation of infected mothers from babies for 14 days.
Ha Lesɗe Inglisiya, feelore ngomna wi'i yo'o hakkika sendugo daada be ɓingel je maray nyau sey hoosa ndu be boɗɗe e sey wonda ha baabal feere ha wakati postpartum je suklare ngam dayinki wala naffuda. Jaangirde ha Cayna feeli sendugo daadiraɓe je nyauɓe be ɓikkon ha nder balɗe 14.
In the US there is also the recommendation that newborns and mothers should be temporarily separated until transmission-based precautions are discontinued, and that where this is not possible the newborn should be kept 2 metres away from the mother.
Ha Lesɗe America wodi feelore je ɓikkon je ɓa danyi keesum be daadiraɓe sey wonda sendama ha nder wakati seeɗa sey to hakkilo ngam sallinol nyau timmi, e to footay waɗa sey daada wona metaa ɗiɗi be mako.
b'COVID-19 surveillance involves monitoring the spread of the coronavirus disease in order to establish the patterns of disease progression.
Aynol b'COVID-19 larni sankittol nyau koronaviriis ngam wanginugo dabare yahde nyau.
The World Health Organization (WHO) recommends active surveillance, with focus of case finding, testing and contact tracing in all transmission scenarios.
Geeɓe Duniyaru do Jam Ɓaandu (WHO) feeli aynol tum, do teffugo irin nyauɓe, lartol e teffol yimɓe je on ngidi be maɓɓe ha nder sallinolji fu.
COVID-19 surveillance is expected to monitor epidemiological trends, rapidly detect new cases, and based on this information, provide epidemiological information to conduct risk assessment and guide disease preparedness.
Aynol COVID-19 wonan do laritugo yahde nyau ndu, larta nyauɓe keese be laugel, e do matinolji ndu, hokka matinolji do nyau ndu ngam lartugo sababu je yahidatta be man e taska ngam nyau ndu.
Syndromic surveillance is done based on the symptoms of an individual that corresponds to COVID-19.
Aynol nyau wondi do mandolji nyau goɗɗo je ɗon naandi be COVID-19.
As of March 2020, the WHO recommends the following case definitions:
Ha maars 2020, WHO feeli ndu bana ɗon limti ndu:
Probable case : "A suspect case for whom testing for the COVID-19 virus is inconclusive" OR "a suspect case for whom testing could not be performed for any reason".
Footi mara: "Goɗɗo je lartay boɗɗum ha nyau COVID-19" MALA "goɗɗo je footi mari e je lartol footay salla ngam uja feere".
Confirmed case: "A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms".
Aandi mari: "Goɗɗo je larti mari nyau COVID-19, ko to o wala sappinugo mandolji nyau".
Direct physical contact with a probable or confirmed case;
Ngidol ɓaandu be goɗɗo je footi mara mala mari nyau;
Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;
Suklare do nyauɗo je footi mara mala je mari nyau COVID-19 je ɗon aandi bila ɓornugo dabareji fadol ɓaandu;
Other situations as indicated by local risk assessments".WHO recommends reporting of probable and confirmed cases of COVID-19 infection within 48 hours of identification.
Kujeji feere bana ɗon limti gal lartolji sababu". WHO ɗon feela matinugo yimɓe je footi mara mala je ɗon mari nyau COVID-19 ha nder njamɗe 48 maandirɗum.
The countries should report on a case-by-case basis as far as possible, but in case of limitation in resources, aggregate weekly reporting is also possible.
Lesɗe sey matina do goɗɗo do goɗɗo bana ko wowa, amma to footay waɗa ngam dabareji wala, moftugo matinolji ha nder asawere footi waɗa.
Some organizations have created crowdsourced apps for syndromic surveillance, where people can report their symptoms to help researchers map areas with concentration of COVID-19 symptoms.
Geeɓeji feere wangini applikasioji waagare ngam aynol mandolji nyau, je yimɓe footi matina mandolji nyau maɓɓe ngam wallugo teffooɓe maanda wakkereji je mandolji COVID-19 ɗon mofti
Virological surveillance is done by using molecular tests for COVID-19.
Aynol yahde viriis ngaɗotto gal huwidugo be lartol molecul ngam COVID-19.
WHO has published resources for laboratories on how to perform testing for COVID-19.
WHO wurtini kujeji ngam cuuɗi lartol do noy ngaɗugo lartol COVID-19.
In the European Union, laboratory confirmed cases of COVID-19 are reported within 24 hours of identification.
Ha nder Kawtal Lesɗe Erop, yimɓe je lartotto ha suudu lartol e je ɗon mari nyau COVID-19 ɗon matini ha nder njamdi 24.
At least 24 countries have established digital surveillance of their citizens.
Pettum man lesɗe 24 wurtini aynol gal ordoji ha ummatore maɓɓe.
The digital surveillance technologies include apps, location data and electronic tags.
Dabareji aynol gal ordoji larni applikasioji, matinolji do wakkere be kujeji feere.
The Center For Disease Control and Prevention in USA tracks the travel information of individuals using airline passenger data.
Ɗowirɗe Aynol e Lartol Nyau ha Lesɗe America ɗon larta matinolji jaahangal yimɓe gal hoccugo matinolji sallooɓe.
In Hong Kong, authorities are requiring a bracelet and an app for all travellers.
Ha Hong Kong, yimɓe ngomna ɗon emma kuje wattugo ha jungo be applikasion ngam waɗɗooɓe jaahangal fu.
A GPS app is used to track the locations of individuals in South Korea to ensure against quarantine breach, sending alerts to the user and to authorities if people leave designated areas.
Applikasion GPS ɗon walla ngam lartugo wonde yimɓe ha South Korea ngam tato watta goɗɗo ha seera meere, gal neldol mandol ha goɗɗo man be yimɓe ngomna yimɓe wurti wakkere ndu.
In Singapore, individuals have to report their locations with photographic proof.
Ha Singapore, yimɓe sey matina wakkere wonde ma
Thailand is using an app and SIM cards for all travelers to enforce their quarantine.
Thailand ɗon huwa be applikasion be karte SIM ngam waɗɗooɓe jaahangal fu ngam aynol wonde maɓɓe ha seera.
Human rights organizations have criticized some of these measures, asking the governments not to use the pandemic as a cover to introduce invasive digital surveillance.
Geeɓe jarfuji neɗɗo lasbini irin dabareji man feere, gal emmugo ngomna'en to ɓe hoosa nyau duniyaru ndu bana suddol nastinugo dabare aynugo yimɓe gal ordoji.
b'A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19).
Baatal b'A COVID-19 lati bana baatal je aandakke boɗɗum ngam nyau koronaviriis 2019 (COVID-19).
Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.
Ko to wala baatal je timmini foondolji ha suudu lekki, wodi dabareji feere-feere nder yahde ngam wurtinugo irin baatal ndu.
In late February 2020, the World Health Organization (WHO) said it did not expect a vaccine against SARS-CoV-2, the causative virus, to become available in less than 18 months.
Ha Feviriye 2020, Geeɓe Duniyaru do Jam Ɓaandu (WHO) wi'i o tammay baatal SARS-CoV-2, viriis je hokki nyau ndu, wonda hiddeko leebi 18.
Five vaccine candidates were in Phase I safety studies in April.
Baatalji foondol joowey ɗon no do ekkitolji jam Yaɓɓorde I ha Aviiril.
COVID-19 was identified in December 2019.
COVID-19 wangi ha Desambre 2020.
A major outbreak spread around the world in 2020, leading to considerable investment and research activity to develop a vaccine.
Sankittol nyau man ha nder duniyaru salli ha 2020, je waɗi ceede jur nasti e aandooɓe ɗon teffa wurtinol baatal.
Many organizations are using published genomes to develop possible vaccines against SARS-CoV-2.
Geeɓeji jur ɗon huwida be genomeji ngam wurtinugo baatalji nyau SARS-CoV-2.
Stated in April, imperatives of the CEPI initiative for vaccine development are speed, manufacturing capacity, deployment at scale, and global access.
Wurti ha Aviiril, feeloji dabare CEPI ngam wanginugo baatal lati jaawal, dabare tagle, huwidugo ummatore jur, keɓɓal ko moy fu.
In April, CEPI scientists reported that 10 different technology platforms were under research and development during early 2020 to create an effective vaccine against COVID-19.
Ha Aviril, aandooɓe CEPI matini daaldaji dabareji 10 ɗon no nder teffol be wanginnol ha fuɗɗam 2020 ngam wurtinugo baatal je ɗon naffa ngam COVID-19.
Major platform targets advanced into Phase I safety studies include:
Daaldal kanduɗum ɗon nder ekkitolji jam Yaɓɓorde I je ɗon larni:
nucleic acid (DNA and RNA) (Phase I developer and vaccine candidate: Moderna, mRNA-1273)
nucleic acid (DNA be RNA) (wanginoowo Yaɓɓorde I be baatal foondol: Moderna, mRNA-1273)
viral vector (Phase I developer and vaccine candidate: CanSino Biologics, adenovirus type 5 vector)
viriis nyau (wanginowo Yaɓɓorde I be baatal foondol: CanSino Biologics, adenovirus type 5 vector)
As reported by CEPI scientists in April, 115 total vaccine candidates are in early stages of development, with 78 confirmed as active projects (79, according to the Milken Institute), and 37 others announced, but with little public information available (presumed to be in planning or being designed).
Bana ɗon matini gal aandooɓe CEPI ha Aviiril, baatalji foondol hawti fu 115 ɗon do taskugo, be 78 lati bana kuɗe je ɗon yahida (79, ha sappinol Milken Institute), be 37 feere ɗon matini, amma be matinolji ummatore ɗon wondi (je nastan ha nder jaahargal mala ɗon suɓɓi).
A Phase I-II trial conducts preliminary safety and immunogenicity testing, is typically randomized, placebo-controlled, and at multiple sites, while determining more precise, effective doses.
Foondol Yaɓɓorɗe I-II ɗon sallina arandere lartolji jam be immunogenecity, lati bana caacaa, aynotto be placebo, e ha wakkereji ɗuɗɗum, ha yakke maandugo hoosugo ndu be boɗɗe.
Phase III trials typically involve more participants, including a control group, and test effectiveness of the vaccine to prevent the disease, while monitoring for adverse effects at the optimal dose.
Foondolji Yaɓɓorɗe III nastini ummatore jur, be geeɓe aynol, e larita naffuda baatal ngam aynugo nyau, e ngam aynugo sababuji je ɗon yahida be man.
Of 79 vaccine candidates in active development (confirmed as of early April 2020), 74 were not yet in human evaluation (still in "preclinical" research).
Ha cakka baatal foondolji 79 do wurtinol (je ɗon aandin ha fuɗɗam Aviiril 2020), 74 nastay ha nder lartol neɗɗo tawon (ha jonta nder teffol "hiddeko suudu lekki").
Around 24 January 2020 in Australia, the University of Queensland announced that it is investigating the potential of a molecular clamp vaccine that would genetically modify viral proteins in order to stimulate an immune reaction.
Gal 24 Zaanviye 2020 ha Australia, University of Queensland matini yo'o o ɗon no teffa molecule je footi wangina baatal je footi saanja proteinji viriis ndu ngam heɓɓa ɓaandu noota.
Around 24 January 2020 in Canada, the International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan announced the commencement of work on a vaccine, aiming to start human testing in 2021.
Gal 24 Zaanviye 2020 ha Kanada, International Vaccine Centre (VIDO-InterVac) ha University Saskatchewan matini yo'o fuɗɗam kugal do baatal, je yiɗi sallinugo foondol do neɗɗo ha 2021.
Vaccine development projects were announced at the Chinese Center for Disease Control and Prevention on 26 January 2020, and the University of Hong Kong on 28 January.
Kuɗe wurtinugo baatal matinama ha Ɗowirɗe Aynol e Lartol Nyau Cayna ha 26 Zaanviye 2020, e University of Hong Kong ha 28 Zaanviye.
Around 29 January 2020, Janssen Pharmaceutical Companies, led by Hanneke Schuitemaker, announced that it had begun work on developing a vaccine.
Gal 29 Zaanviye 2020, Janssen Pharmaceutical Companies, je Hanneke Schuitemaker lati arduɗo majuum, wi'i o fuɗɗi huwidugo do baatal ngu.
Janssen is co-developing an oral vaccine with its biotechnology partner, Vaxart.
Janssen ɗon huwida do baatal gal hunduko be bero mako, Vaxart.
On 18 March 2020, Emergent BioSolutions announced a manufacturing partnership with Vaxart to develop the vaccine.
Ha 18 Maars, Emmergent BioSolution matini huwidugo be Vaxart ngam wurtinugo baatal.
On 8 February 2020, the laboratory OncoGen in Romania published a paper on the design of a vaccine with similar technology to the one used for cancer neoantigen vaccination therapy.
Ha 8 Feviriye 2020, suudu lartol OncoGen in Romania wurtini batakkewol feere do dabare wurtinugo baatal be irin teknik je baatal neoantigen hurgol sankara.
On 25 March the head of the research institute announced that they had finalized the synthesis of the vaccine and were beginning the tests.
Ha 25 Maars ɗowuwo geeɓe teffol matini yo'o ɓe timmini lartol baatal e fuɗɗi be lartolji timmi.
On 27 February 2020, a Generex subsidiary company, NuGenerex Immuno-Oncology, announced they were beginning a vaccine project to create an Ii-Key peptide vaccine against COVID-19.
Ha 27 Feviriye 2020, Generex subsidiary company, NuGenerex Immuno-Oncology, matini yo'o ɓe ɗon fuɗɗa kuɗe do teffol baatal ngam wanginugo baatal li-Key peptide ngam nyau COVID-19.
They wanted to produce a vaccine candidate that could be tested in humans "within 90 days."
Ɓe yiɗi wurtinugo baatal foondol je footi en larta do yimɓe "ha nder balɗe 90".
On 5 March 2020, Washington University in St. Louis announced its projects to develop a vaccine.
Ha 5 Maars 2020, Washington University in St. Louis matini kuɗe mako ngam wurtinugo baatal.
On 5 March 2020, the United States Army Medical Research and Materiel Command at Fort Detrick and the Walter Reed Army Institute of Research in Silver Spring, both in western Maryland, announced they were working on a vaccine.
Ha nyalade 5 lewru maars, Arduɗo Geebe Teffol Soje Jam Bandu Lesɗi America ha Fort Detrick be Suudu Jaangirde Teffol Soje Walter Reed ha Silver Spring, ɗiɗi fu ha Marvland je hirnaange, matini yo'o ɓe ɗon huwa ngam wurtinugo baatal.
Around 10 March 2020, Emergent Biosolutions announced that it had teamed with Novavax Inc.
Gal 10 Maars 2020, Emergent Biosolutions matini huwidugo be Novavax Inc.
in the development and manufacture of a vaccine.
ngam dabare wanginugo e wurtinugo baatal.
The partners further announced plans for preclinical testing and a Phase I clinical trial by July 2020.
Bero'en mako matini yo'o jaahargal lartol hiddeko suddu lekki be foondol Yaɓɓorde I ha suudu lekki gal Zwiiye 2020.
On 12 March 2020, India's Health Ministry announced they are working with 11 isolates, and that even on a fast track it would take at least around one-and-a-half to two years to develop a vaccine.
Ha 12 Maars 2020, Geeɓe jam ɓaandu India matini yo'o ɓe ɗon huwa be baatalji 11, e ko to yaawi ma footi neeɓa duɓɓi be reeta mala duɓɓi ɗiɗi ngam wurtinugo baatal.
On 12 March 2020, Medicago, a biotechnology company in Quebec City, Quebec, reported development of a coronavirus-like particle under partial funding from the Canadian Institutes for Health Research.
Ha 12 Maars 2020, Medicago, biotechnology company ha Quebec City, Quebec, matini kugal do wurtinugo kuje feere je ɗon naandi koronaviriis je Canadian Institutes for Health Research hokki ceede seeɗa.
The vaccine candidate is in laboratory research, with human testing planned for July or August 2020.
Baatal foondol ɗon ha nder suudu teffol, be lartolji do yimɓe ɗon hasdi ngam Zwiiye mala Uut 2020.
Earlier that week, The Guardian reported that the US President Donald Trump had offered CureVac "'large sums of money' for exclusive access to a Covid-19 vaccine", against which the German government protested.
Ha fuɗɗam asawere ndu, The Guardian matini yo'o Jagorɗo Lesɗe America Donald Trump hokki ha CureVac "ceede ɗuɗɗum ngam wurtinugo baatal COVID-19", je ngomna Jaamani yarday sam.
On 17 March 2020, American pharmaceutical company Pfizer announced a partnership with German company BioNTech to jointly develop a mRNA-based vaccine.
Ha 17 Maars 2020, American pharmaceutical company Pfizer matini huwidugo be German company BioNTech ngam wurtinugo baatal mRNA.
mRNA-based vaccine candidate BNT162, currently in pre-clinical testing with clinical trials expected to begin in April 2020.
Baatal foondol mRNA BNT162, jonta ha nder lartol hidekko suddu lekki be foondolji je hasdi wurtugo ha fuɗɗam Aviiril 2020.
In Italy on 17 March 2020, Takis Biotech, an Italian biotech company announced they will have pre-clinical testing results in April 2020 and their final vaccine candidate could begin human testing by fall.
Ha Italy ha 17 Maars 2020, Takis Biotech, biotech company Italy matini yo'o ɓe maran sappinolji lartol hiddeko suudu lekki ha Aviiril 2020 e baatal foondol je ragare footi fuɗɗa hiddeko timminol hittande nde.
In France on 19 March 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) announced a US$4.9 million investment in a COVID-19 vaccine research consortium involving the Institut Pasteur, Themis Bioscience (Vienna, Austria), and the University of Pittsburgh, bringing CEPI's total investment in COVID-19 vaccine development to US$29 million.
Ha Faransa ha 19 Maars 2020, Coalition for Epidemic Preparedness Innovations (CEPI) matini wurtinugo milionji US$4.9 ngam teffol do baatal COVID-19 be geeɓe bana Institut Pasteur, Themis Bioscience (Vienna, Austria), be University of Pittsburgh, ko ɗon hawti moftol ceede CEPI ngam wanginugo baatal COVID-19 ha milionji US$29.
CEPI's other investment partners for COVID-19 vaccine development are Moderna, Curevac, Inovio, Novavax, the University of Hong Kong, the University of Oxford, and the University of Queensland.
Geeji feere je CEPI ɗon huwida be maɓɓe ngam wurtinol baatal nyau COVID-19 lati Moderna, Curevac, Inovio, Novavax, University of Hong Kong, University of Oxford, be University of Queensland.
On 20 March 2020, Russian health officials announced that scientists have begun animal testing of six different vaccine candidates.
Ha 20 Maars 2020, yimɓe ngomna Russiya matini yo'o aandooɓe fuɗɗi lartolji do daabaji be baatalji foondol joowey go'o.
Imperial College London researchers announced on 20 March 2020 that they are developing a self-amplifying RNA vaccine for COVID-19.
Teffooɓe Imperial College London researchers matini ha 20 Maars 2020 yo'o ɓe ɗn no waɗa dabare wurtinugo baatal NRA je ɗon yajja feere maɗa ngam COVID-19.
The vaccine candidate was developed within 14 days of receiving the sequence from China.
Ko footi wona baatal ndu huwidotto ha nder balɗe 14 diga jaɓɓugo kuje man ha Cayna.
In late March, the Canadian government announced C$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian companies and universities, such as the Medicago and University of Saskatchewan initiatives.
Ha ragare Maars, ngomna Kanada matini wurtinugo milionji C$275 bana wallende kuɗe teffol 96 ngam dabareji jam ɓaandu ngam COVID-19, be baatalji foondol jur ha nder geeɓeji be jam'iareji Kanadiya'en bana dabareji Medicago and University of Saskatchewan.
Around the same time, the Canadian government announced C$192 million specifically for developing a COVID-19 vaccine, with plans to establish a national "vaccine bank" of several new vaccines that could be used if another coronavirus outbreak occurs.
Ha wakati ndu, ngomna Kanada matini wurtinugo milionji C$192 ngam wanginugo baatal COVID-19, be jaahargalji mahugo "siggorde baatalji" ngam baatalji keese ɗuɗɗum je footi naffa to nyau koronaviriis feere wangi.
On 2 April 2020, researchers at the University of Pittsburgh School of Medicine reported on testing of PittCoVacc, a possible COVID-19 vaccine in mice, stating that "MNA delivered SARS-CoV-2 S1 subunit vaccines elicited potent antigen-specific antibody responses [in the mice] that were evident beginning 2 weeks after immunization."
Ha 2 Aviiril 2020, teffooɓe ha University of Pittsburgh School of Medicine matini ngam lartugo PittCoVacc, baatal COVID-19 ha doomɓi, gal wi'ugo yo'o "MNA wurtini geeɓe baatalji SARS-CoV-2 S1 je ɗon tutta fadooɓe ɓaandu je ɗon mari antigene je ɗon mari semɓe [ha nder doomɓi] je fuɗɗan asaweji 2 ha ɓawo fadol."
In Canada on 16 April 2020, the University of Waterloo School of Pharmacy announced design of a DNA-based vaccine candidate as a possible nasal spray.
Ha Kanada ha 16 Aviril 2020, Jam'iare Waterloo School of Pharmacy matini sappinol DNA ko footi wona baatal je lati bana lekki fuffugo ha nder kine.
Using bacteriophages, the DNA will be designed to replicate inside human bacteria to produce harmless virus-like particles, which may stimulate the immune system to produce antibodies against the SARS-CoV-2 virus.
Huwugo be bacteriophageji, DNA naffan ngam nuftugo ha nder bakteriyaji neɗɗo ngam wurtinugo coolaaje je naandi viriis je wala nyaɗugo, je footi sembintina dabare fadol ɓaandu ngam wurtinugo fadooɓe ɓaandu ngam viriis SARS-CoV-2.
In March 2020, the US government, industry, and three universities pooled resources to access supercomputers from IBM, combined with cloud computing resources from Hewlett Packard Enterprise, Amazon, Microsoft, and Google.
Ha Maars 2020, ngomna Lesɗe America, suudu tagle, be jam'iareji hawti sembe maɓɓe ngam nastugo ha nder ordoji nyaɗum gal IBM, hawti be dabareji huwidol do hawo Hewlett Packard Enterprise, Amazon, Microsoft, be Google.
Some vaccines have heterologous effects, also called non-specific effects.
Baatalji feere ɗon mari sababuji feere, e ewnotto bo'o sababuji je ɗon saanja.
That means they can have benefits beyond the disease they prevent.
Bana wi'ugo ɓe footi mara ribaji ha gaɗɗa nyau je ɗon ayna.
A further randomized trial in Australia is seeking to enrol 4,170 healthcare workers.
Foondol feere ha Australia ɗon teffa nastinugo huwooɓe jam ɓaandu 4170.
It is possible vaccines in development will not be safe or effective.
Footi bo'o baatalji je do wurtugo footi wonatta jam mala mara naffuda.
Early research to assess vaccine efficacy using COVID-19-specific animal models, such as ACE2-transgenic mice, other laboratory animals, and non-human primates, indicate a need for biosafety-level 3 containment measures for handling live viruses, and international coordination to ensure standardized safety procedures.
Teffolji arandere ngam lartugo naffitirki baatal gal hoosugo irin COVID-19 je yahidan be daabaji bana doombi ACE2-transgenic., daabaji suudu lartolji feere, be wandu'en je nastay nder asngol neɗɗo, sappina haaje ngam dabareji darnugo biosafety-level 3 ngam memmugo viriisji je ɗon nyeeɗa, be fadol duniyaru ngam hollugo dabareji jam je ɗon aandi.
Vaccines against SARS and MERS have been tested in non-human animal models.
Baatalji ngam SARS be MERS lartama ha nder naandolji je wonay goɗɗo.
As of 2020, there is no cure or protective vaccine for SARS that has been shown to be both safe and effective in humans.
Ha 2020, wala hurgol mala baatal aynugo ngam SARS je sappinama ɗon jam e naffan neɗɗo.
According to research papers published in 2005 and 2006, the identification and development of novel vaccines and medicines to treat SARS was a priority for governments and public health agencies around the world.There is also no proven vaccine against MERS.
Bana sappinol batakkeji teffoln2005 be 2006, maandirɗum be wanginol baataji keese be lekki hurgol SARS lati aranool nummol ngomna'en be geeɓeji jam ɓaandu ummatore ha nder lesdi. Fahin, wala baatal je ɗon aandin ngam MERS.
When MERS became prevalent, it was believed that existing SARS research may provide a useful template for developing vaccines and therapeutics against a MERS-CoV infection.
Ha wakati je MERS wangi, yimɓe tammi yo'o teffolji do SARS footi dabare feere ngam wurtinugo baatalji mala lekki nyau MERS-CoV.
As of March 2020, there was one (DNA based) MERS vaccine which completed phase I clinical trials in humans, and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (ChAdOx1-MERS, BVRS-GamVac), and one MVA-vectored (MVA-MERS-S).
Ha 20 Maars 2020, wodi no baatal MERS (je wondi do DNA) je timmini foondolji yaɓɓorde I ha suudu lekki, be feere en tati, je fu woni baatalji viriis, adenoviriis, (ChAdOx1-MERS, BVRS-GamVac), be MVA-vectored (MVA-MERS-S) woore.
Social media posts have promoted a conspiracy theory claiming the virus behind COVID-19 was known and that a vaccine was already available.
Sappinolji bindi ha hubaru ummatore wurtini ngewte dabare gal wi'ugo viriis je ɗon wondi ha ɓawo COVID-19 ɗon no aandi e baatal man ɗon timmi.
The patents cited by various social media posts reference existing patents for genetic sequences and vaccines for other strains of coronavirus such as the SARS coronavirus.
Aandinolji je ɗon limti ha do daaldal ummatore ɗon lorta ha aandinolji je ɗon no wondi aran ngam ta'irde geneji ngam asli coronaviriis feere bana koronaviriis SARS.
b'Coronaviruses are a group of related viruses that cause diseases in mammals and birds.
Koronaviriisji b' lati geeɓe irin viriisji je ɗon hokka nyauji ha daabaje be cooli.
In humans, coronaviruses cause respiratory tract infections that can range from mild to lethal.
Ha nder nder neɗɗo, koronaviriis ɗon hokka nyau lawol pofɗe je footi umma diga seeɗa ha mayde.
Mild illnesses include some cases of the common cold (which has other possible causes, predominantly rhinoviruses), while more lethal varieties can cause SARS, MERS, and COVID-19.
Nyauji je nyaɗay jur larni nyau bana ndamba (je footi mara ujaji feere, ɓurna fu rhinoviriisji), ha wakati feere asli feere footi hokka SARS, MERS, BE COVID-19.
Symptoms in other species vary: in chickens, they cause an upper respiratory tract disease, while in cows and pigs they cause diarrhea.
Mandolji ha nder daabaji feere ɗon saanja: ha goortoɗe, ɓe ɗon hokka nyau lawol pofɗe dow, ha na'i be gaduji bo'o ɗon hokka caarol.
There are yet to be vaccines or antiviral drugs to prevent or treat human coronavirus infections.
Wala baatal mala lekki mbarugo virisji ngam aynugo mala hurgugo neɗɗo ngam nyau koronaviriis.
Coronaviruses constitute the subfamily Orthocoronavirinae, in the family Coronaviridae, order Nidovirales, and realm Riboviria.
Koroonaviriis ɗon woni ha asngol Orthocoronavirinae, geeɓe Coronaviridae, caalaje Nidovirales, e lamorde Riboviria.
They are enveloped viruses with a positive-sense single-stranded RNA genome and a nucleocapsid of helical symmetry.
Be lati viriisji je ɗon suddi genome je ɗon mari RNA be kosngal gooto be nucleocapsid be ɓaandu yirlama.
The genome size of coronaviruses ranges from approximately 26 to 32 kilobases, one of the largest among RNA viruses.
Maunugo genome koronaviriis ɗon fuɗɗa diga kilobaseji 26 ha 32, gooto ha cakka viriisji RNA je ɓuri yajjugo.
They have characteristic club-shaped spikes that project from their surface, which in electron micrographs create an image reminiscent of the solar corona from which their name derives.
Ɓe ɗon mari bana gi'e ha do do ɓaandu maɓɓe, je to wati nder electon micrographji ɗon waɗa bana naandi foto naange je ɗon jayna ko waɗi inde maɓɓe.
Coronaviruses were first discovered in the 1930s when an acute respiratory infection of domesticated chickens was shown to be caused by infectious bronchitis virus (IBV).
Koronaviriisji tawotto aranool gal 1930 ha wakati je ɓe tawi nyau pofde ha nder goortoɗe saare bana wangi gal viriis bronchitis je ɗon raɓɓa (IBV).
In the 1940s, two more animal coronaviruses, mouse hepatitis virus (MHV) and transmissible gastroenteritis virus (TGEV), were isolated.Human coronaviruses were discovered in the 1960s.
Gal 1940, wodi koronaviriisji daabaji feere, viriis hengre doombi (MHV) be viriis gartroenteritis je ɗon raɓɓa (TGEV), tawotto. Koronaviriisji neɗɗo tawama ja 1960.
The earliest ones studied were from human patients with the common cold, which were later named human coronavirus 229E and human coronavirus OC43.
Arandere je ɗon jaangini wurti ha nyauɓe je mari no ndamba meere, je ewnotto koronaviriis 229E be koronaviriis neɗɗo OC43.
They were first imaged by Scottish virologist June Almeida at St. Thomas Hospital in London.
Arandere fotoji maɓɓe wurti gal jaanginoowo viriis Scotland June Almeida ha St. Thomas Hospital ha London.